OQROGet OQRO Pro
Politician trade (House)

Supernus Pharmaceuticals, Inc. (SUPN)Rep. Gilbert Cisneros (CA31) disclosed a purchase $1K–$15K

Rep. Gilbert Cisneros (CA31) disclosed a purchase of Supernus Pharmaceuticals, Inc. in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
35 days
Disclosure lag
Traded
Mar 3, 2026
Disclosed
Apr 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 11, 2025CongressDisclosed purchase of SUPN — reported range $1,001 - $15,000
  2. Feb 12, 2026Company filing · Form 8-K · ResultsReported its results
  3. Feb 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 18, 2026, the Compensation Committee (the “Committee”) of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) recommended, and the Board of Directors (the “Board”) approved, modifications of the compensation of the Company’s executive officers, as follows: The annual base salary of Jack A. Khattar, the Company’s President and Chief Executive Officer, was increased from $1,036,000 to $1,067,100.”
  4. Feb 24, 2026Company filing · Form 8-K · ResultsReported its results
  5. Mar 3, 2026 · this disclosureCongressDisclosed purchase of SUPN — reported range $1,001 - $15,000

What came next

  1. Apr 1, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement“Completion of Acquisition or Disposition of Asset. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this”
  2. Apr 22, 2026Company filing · Form 8-K · ResultsReported its results
  3. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  4. May 17, 2026Company filing · Form 8-K · New debtTook on new debt or obligations
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Supernus Pharmaceuticals, Inc.

For Supernus Pharmaceuticals, Inc., OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SUPN page.

Other recent filings by Rep. Gilbert Cisneros (CA31)

The full history of Rep. Gilbert Cisneros (CA31) is on the profile page.

How this filing works

Other disclosures at Supernus Pharmaceuticals, Inc.

Everything OQRO holds on this company is on its SUPN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data